~~<i id='987DD753A8'><strike id='987DD753A8'><tt id='987DD753A8'><pre id='987DD753A8'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：entertainment 2025-08-25 07:19:50 Page View：524

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Stanford updates investigation of president’s past research
Next article： Heart attack and stroke risk calculators need revising

explore

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

The new HIV moral panic

Gilead'sPrEPpillTruvadaJustinSullivan/GettyImagesInMay,justbeforePrideMonth,theCentersforDiseaseCont

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

The kidney, in all its complexity, is captured in a new atlas

AdobeThekidneysaresomeofthemostarchitecturallycomplexorgansinthehumanbody—intricateinawaythatbecomes